KRW 15050.0
(-4.57%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 18.1 Billion KRW | 153.33% |
2022 | 7.14 Billion KRW | 231.3% |
2021 | 2.15 Billion KRW | 1483.73% |
2020 | -155.87 Million KRW | 93.58% |
2019 | -2.42 Billion KRW | -242964735200.0% |
2018 | 1.00 KRW | 0.0% |
2017 | 1.00 KRW | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2023 Q4 | 18.1 Billion KRW | 131.86% |
2023 Q1 | 9.87 Billion KRW | 38.17% |
2023 Q3 | 7.8 Billion KRW | -2.98% |
2023 Q2 | 8.04 Billion KRW | -18.49% |
2022 Q1 | 16.32 Billion KRW | 656.68% |
2022 Q2 | 15.19 Billion KRW | -6.93% |
2022 FY | 7.14 Billion KRW | 231.3% |
2022 Q4 | 7.14 Billion KRW | -39.48% |
2022 Q3 | 11.8 Billion KRW | -22.27% |
2021 Q1 | 6.3 Billion KRW | 4147.64% |
2021 FY | 2.15 Billion KRW | 1483.73% |
2021 Q4 | 2.15 Billion KRW | -89.29% |
2021 Q3 | 20.14 Billion KRW | 40.19% |
2021 Q2 | 14.37 Billion KRW | 127.76% |
2020 Q4 | -155.87 Million KRW | -103.39% |
2020 Q3 | 4.6 Billion KRW | 0.0% |
2020 FY | -155.87 Million KRW | 93.58% |
2019 FY | -2.42 Billion KRW | -242964735200.0% |
2019 Q4 | - KRW | 0.0% |
2018 FY | 1.00 KRW | 0.0% |
2017 FY | 1.00 KRW | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ORIENT BIO Inc. | 3.65 Billion KRW | -395.374% |
Green Cross Holdings Corporation | 579.72 Billion KRW | 96.877% |
Green Cross Holdings Corporation | 516.24 Billion KRW | 96.493% |
Pharmicell Co., Ltd. | 20.87 Billion KRW | 13.268% |
Green Cross Corporation | 516.24 Billion KRW | 96.493% |
GeneOne Life Science, Inc. | 14.89 Billion KRW | -21.522% |
Celltrion, Inc. | 3041.45 Billion KRW | 99.405% |
Samsung Biologics Co.,Ltd. | 2641.36 Billion KRW | 99.315% |
SK bioscience Co.,Ltd. | 80.64 Billion KRW | 77.553% |
SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | 82.343% |